• 1. Acentric and chiral heterometallic inorganic–organic hybrid frameworks mediated by alkali or alkaline earth ions: synthesis and NLO properties
  Huabin Zhang,Shaowu Du CrystEngComm, 2014,16, 4059-4068
• 2. An approach to biodegradable star polymeric architectures using disulfide coupling?
  Jingquan Liu,Huiyun Liu,Zhongfan Jia,Volga Bulmus,Thomas P. Davis Chem. Commun., 2008, 6582-6584
• 3. Acenaphthenic hopanoids, a novel series of aromatised
  Teresita Carrillo-Hernández,Philippe Schaeffer,Pierre Albrecht Chem. Commun., 2001, 1976-1977
• 4. An anti-ultrasonic-stripping effect in confined micro/nanoscale cavities and its applications for efficient multiscale metallic patterning?
  Quan Xiang,Yiqin Chen,Zhiqin Li,Kaixi Bi,Guanhua Zhang,Huigao Duan Nanoscale, 2016,8, 19541-19550
• 5. An artificial enzyme cascade amplification strategy for highly sensitive and specific detection of breast cancer-derived exosomes?
  Huiying Xu,Lu Zheng,Yu Zhou,Bang-Ce Ye Analyst, 2021,146, 5542-5549

Introduction to N-(6-Bromo-7-methylimidazo[1,2-a]pyridin-2-yl)-2,2,2-trifluoroacetamide (CAS No. 2006278-09-5)

N-(6-Bromo-7-methylimidazo[1,2-a]pyridin-2-yl)-2,2,2-trifluoroacetamide, identified by its CAS number 2006278-09-5, is a compound of significant interest in the field of pharmaceutical chemistry and medicinal research. This molecule has garnered attention due to its structural complexity and potential biological activities, making it a valuable candidate for further investigation in drug discovery and development.

The core structure of N-(6-Bromo-7-methylimidazo[1,2-a]pyridin-2-yl)-2,2,2-trifluoroacetamide consists of an imidazopyridine scaffold, which is a heterocyclic compound featuring both imidazole and pyridine rings fused together. The presence of a bromine atom at the 6-position and a methyl group at the 7-position of the imidazopyridine ring introduces specific electronic and steric properties that can influence its reactivity and interactions with biological targets. Additionally, the amide functionality at the 2-position of the imidazopyridine ring provides a site for further chemical modification, enabling the synthesis of derivatives with tailored properties.

In recent years, there has been a growing interest in imidazopyridine derivatives due to their diverse biological activities. These compounds have shown promise in various therapeutic areas, including anticancer, antiviral, and anti-inflammatory applications. The introduction of fluorine atoms in the trifluoroacetamide moiety further enhances the pharmacological potential of this class of molecules by improving metabolic stability and binding affinity to biological targets.

One of the most compelling aspects of N-(6-Bromo-7-methylimidazo[1,2-a]pyridin-2-yl)-2,2,2-trifluoroacetamide is its potential as a scaffold for drug discovery. The bromine substituent at the 6-position allows for easy functionalization via cross-coupling reactions, such as Suzuki or Buchwald-Hartwig couplings, which are widely used in medicinal chemistry to introduce diverse molecular fragments. This flexibility makes it an attractive starting point for generating libraries of compounds for high-throughput screening.

The trifluoroacetamide group not only contributes to the metabolic stability of the molecule but also influences its solubility and bioavailability. Fluorinated amides are known to enhance binding interactions with proteins due to their ability to form strong hydrogen bonds and dipole-dipole interactions. This property is particularly valuable in drug design, where optimizing binding affinity can lead to more effective therapeutic agents.

Recent studies have highlighted the importance of imidazopyridine derivatives in oncology research. For instance, several imidazopyridines have been reported to inhibit kinases and other enzymes involved in cancer cell proliferation and survival. The structural features of N-(6-Bromo-7-methylimidazo[1,2-a]pyridin-2-yl)-2,2,2-trifluoroacetamide, including the brominated imidazopyridine core and the fluorinated amide group, suggest that it may exhibit similar inhibitory activities. Further investigation into its biological profile could uncover new therapeutic opportunities in cancer treatment.

Beyond cancer research, N-(6-Bromo-7-methylimidazo[1,2-a]pyridin-2-yl)-2,2,2-trifluoroacetamide may also have applications in other therapeutic areas. For example, imidazopyridines have been explored as antiviral agents due to their ability to interfere with viral replication cycles. The presence of fluorine atoms could enhance the antiviral activity by improving drug resistance profiles against enzymatic degradation.

The synthesis of N-(6-Bromo-7-methylimidazo[1,2-a]pyridin-2-yl)-2,2,2-trifluoroacetamide involves multi-step organic transformations that highlight the synthetic versatility of imidazopyridine derivatives. Key steps include bromination of the imidazopyridine ring followed by condensation with trifluoroacetonitrile under appropriate conditions. The use of palladium-catalyzed cross-coupling reactions allows for precise functionalization at specific positions on the scaffold.

In conclusion, N-(6-Bromo-7-methylimidazo[1，

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)